DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets

Allison R. Hanaford, Tenley C. Archer, Antoinette Price, Ulf D. Kahlert, Jarek Maciaczyk, Guido Nikkhah, Jong Wook Kim, Tobias Ehrenberger, Paul A. Clemons, Vlado Dančík, Brinton Seashore‐Ludlow, Vasanthi S. Viswanathan, Michelle L. Stewart, Matthew G. Rees, Alykhan Shamji, Stuart L. Schreiber, Ernest Fraenkel, Scott L. Pomeroy, Jill P. Mesirov, Pablo Tamayo, Charles G. Eberhart, Eric H. RaabeClinical 2016 · DOI

Abstract

We present a new method to generate genetically accurate models of rare tumors, and a companion computational methodology to find therapeutic interventions that target them. We validated our human neural stem cell model of MYC-driven Group 3 medulloblastoma and showed that CDK 4/6 inhibitors are active against this subgroup. Our results suggest that palbociclib is a potential effective treatment for poor prognosis MYC-driven Group 3 medulloblastoma tumors in carefully selected patients. Clin Cancer Res; 22(15); 3903-14. ©2016 AACR.
BibTeX
@inproceedings{hanaford2016discovering,
  author = {Allison R. Hanaford and Tenley C. Archer and Antoinette Price and Ulf D. Kahlert and Jarek Maciaczyk and Guido Nikkhah and Jong Wook Kim and Tobias Ehrenberger and Paul A. Clemons and Vlado Dančík and Brinton Seashore‐Ludlow and Vasanthi S. Viswanathan and Michelle L. Stewart and Matthew G. Rees and Alykhan Shamji and Stuart L. Schreiber and Ernest Fraenkel and Scott L. Pomeroy and Jill P. Mesirov and Pablo Tamayo and Charles G. Eberhart and Eric H. Raabe},
  title = {{DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with <i>In Silico</i> Analysis to Identify Novel Therapeutic Targets}},
  booktitle = {Clinical},
  year = {2016},
  doi = {10.1158/1078-0432.ccr-15-3011},
}

Loading related content...

Figure